PCRX
NASDAQ · Pharmaceuticals
Pacira Biosciences Inc
$24.44
-1.05 (-4.12%)
Financial Highlights (FY 2026)
Revenue
613.61M
Net Income
5.94M
Gross Margin
79.4%
Profit Margin
1.0%
Rev Growth
+2.9%
D/E Ratio
0.54
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 79.4% | 79.4% | 52.8% | 52.8% |
| Operating Margin | 1.0% | 0.9% | 24.9% | 27.7% |
| Profit Margin | 1.0% | 0.9% | 19.1% | 15.5% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 613.61M | 596.31M | 216.59M | 180.44M |
| Gross Profit | 487.14M | 473.41M | 114.35M | 95.27M |
| Operating Income | 6.07M | 5.31M | 54.00M | 50.00M |
| Net Income | 5.94M | 5.20M | 41.33M | 27.91M |
| Gross Margin | 79.4% | 79.4% | 52.8% | 52.8% |
| Operating Margin | 1.0% | 0.9% | 24.9% | 27.7% |
| Profit Margin | 1.0% | 0.9% | 19.1% | 15.5% |
| Rev Growth | +2.9% | +2.9% | +14.7% | +11.2% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 162.44M | 162.44M | 314.39M | 342.78M |
| Total Equity | 302.50M | 302.50M | 342.17M | 361.79M |
| D/E Ratio | 0.54 | 0.54 | 0.92 | 0.95 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 58.18M | 53.72M | 75.27M | 64.71M |
| Free Cash Flow | — | — | 28.35M | 34.26M |